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Background:We investigated the effect of chronic kidney disease (CKD) on morbidity and mortality following
transcatheter aortic valve implantation (TAVI) including patients on haemodialysis, often excluded from
randomised trials.
Methods and results:Weperformed a retrospective post hoc analysis of all patients undergoing TAVI at our centre
between 2008 and 2012. 118 consecutive patients underwent TAVI; 63were considered as having (CKD) and 55
not having (No-CKD) signiﬁcant pre-existing CKD, (deﬁned as estimated glomerular ﬁltration rate
(eGFR) b 60 mL/min/1.73 m2). Chronic haemodialysis patients (n = 4) were excluded from acute kidney injury
(AKI) analysis. Following TAVI, in CKD and No-CKD patients respectively, AKI occurred in 23.7% and 14.5% (p=
0.455) and renal replacement therapy (RRT) was necessary in 8.5% and 3.6% (relative risk (RR) [95% CI] = 2.33
[0.47–11.5], p = 0.440); 30-day mortality rates were 6.3% and 1.8% (p = 0.370); and 1-year mortality rates
were 17.5% and 18.2% (p = 0.919). Patients who developed AKI had a signiﬁcantly increased risk of 30-day
(12.5% vs. 1.1%, p = 0.029) mortality. We found the presence of diabetes (odds ratio (OR) [95% CI] = 4.58
[1.58–13.3], p= 0.005) and elevated baseline serum creatinine (OR [95% CI] = 1.02 [1.00–1.03], p= 0.026) to
independently predict AKI to statistical signiﬁcance by multivariate analysis.
Conclusion: TAVI is a safe, acceptable treatment for patients with pre-existing CKD, however caution must be
exercised, particularly in patients with pre-existing diabetes mellitus and elevated pre-operative serum
creatinine levels as this confers a greater risk of AKI development, which is associated with increased short-
term post-operative mortality.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aortic stenosis (AS) is the commonest cause of valvular heart disease
in the elderly with prevalence estimated up to 8.1% at 85 years [1]. In
patients with severe symptomatic AS the prognosis is poor for those
managed conservatively, with 1-year survival only 60% and 5-year sur-
vival 32% [1]. Previously, surgical aortic valve replacement (SAVR), with
orwithout concomitant coronary artery bypass surgery (CABG)was the
only treatment modality, however for patients declined SAVR on the
grounds of prohibitively high surgical risk, medical therapy including
balloon valvuloplasty offered little or no improvement on survival [2].
One in three patients with severe valvular heart disease does not havehe reliability and freedom from
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Rahman).
land Ltd. This is an open access articlsurgery due to comorbidities [3]. The development of percutaneous
techniques for aortic valve replacement has offered new hope to this
cohort of patients. Transcatheter aortic valve replacement (TAVI) is
superior to medical therapy alone [2]. This older and potentially frailer
cohort, with a greater burden of co-morbidity has provided an addition-
al challenge in patient selection and management following valve re-
placement. More than 30,000 TAVI procedures have been performed
over the last 10 years [4,5].
Acute kidney injury (AKI) is associated with adverse outcomes even
when transient [6] andmore sowhen associatedwith the need for renal
replacement therapy (RRT) [7]. The presence of pre-existing chronic
kidney disease (CKD) is known to be a factor predisposing patients to
AKI following cardiothoracic surgery [8], has been shown to increase
the risk of mortality following SAVR [9,10] and is correlated with
worse outcome following TAVI [11]. AKI can occur in up to one in
three patients undergoing cardiac surgery [3] with a signiﬁcant propor-
tion at risk of requiring long-term haemodialysis [12–14]. AKI following
cardiac surgery is an independent predictor of in-hospital [15],mid- and
long-term mortality in the setting of contrast-induced nephropathye under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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predictor of AKI [20,21] and exists in 10–25% of patients undergoing
TAVI [15,19,22]. CKD represents other challenges, with the burden of
aortic calciﬁcation being higher in this cohort of patients [23–25] and
particularly in those undergoing chronic haemodialysis [26,27].
Recent studies vary in the frequency of AKI following TAVI, reported
as low as 7% [28] and as high as 41% [29], however different deﬁnitions
of AKI have been used in different studies with heterogeneous popula-
tions and varying study sizes. This rate may potentially still be lower
than SAVR in patients with pre-existing CKD [15]. TAVI can involve
the use of contrast media, episodes of hypotension and haemodynamic
stress, ischaemia and possible perioperative volume depletion thereby
putting patients at risk of developing AKI.
The Valve Academic Research Consortium (VARC) has published
criteria deﬁning standards for endpoints following valve TAVI [30], and
recently updated these as The Valve Academic Research Consortium-2
(VARC-2) Consensus Document [31]. This updates the previous deﬁni-
tion of AKI following TAVI with the use of the Acute Kidney Injury Net-
work (AKIN) criteria (see Supplementary Table 1; all subsequent tables
are in the ‘Tables’ document, all ﬁgures in the ‘Figures’ document and
supplementary data in the ‘Supplementary Data’ document) in favour
over the ‘modiﬁed’ RIFLE criteria [32] and extends the period through
which AKI can be deﬁned from 72 h to 7 days post-procedure. Studies
have suggested that smaller changes in serum creatinine than those
categorised by RIFLE may be important in predicting adverse outcome,
supporting a shift towards the use of AKIN criteria [33–35].
We aimed to identifywhether the presence of pre-existing renal im-
pairment inﬂuenced the development of AKI. In addition, we assessed
whether there was an association between the presence of pre-
existing renal impairment and outcome in terms of morbidity andmor-
tality and whether the development of AKI inﬂuenced morbidity and
mortality.
2. Methods
2.1. Study population and deﬁnitions
We present our experience of TAVI in consecutive patients with and
without pre-existing CKD performed betweenDecember 2007 and June
2012. We performed a post hoc analysis of our prospectively collected
registry data and deﬁned the presence of CKD according to the estimat-
ed glomerular ﬁltration rate (eGFR) calculated using the abbreviated
Modiﬁcation of Diet in Renal Disease (MDRD) equation [36]. Patients
were divided into those with established CKD Stage 3 or above (“CKD”
group, estimated glomerular ﬁltration rate (eGFR) b 60 mL/min/
1.73 m2) and those in CKD Stage 2 or below (“No-CKD” group, eGFR N
60 mL/min/1.73 m2), as deﬁned by the Renal Association (UK) [37].
Mortality andmorbidity data were obtained from the on-going registry
entries, hospital records and telephone calls to patients' General Practi-
tioners. AKI was deﬁned according to the AKIN classiﬁcation (Supple-
mentary Table 1) as outlined by VARC-2 [31]. Importantly, this deﬁnes
patients who required RRT following TAVI as suffering Stage 3 AKI irre-
spective of changes in serum creatinine or urine output. The ‘baseline
serum creatinine’ reading was taken as the ﬁrst reading obtained
upon admission, usually the day before the TAVI procedure, so as to
avoid any confounding factors that may inﬂuence this (e.g. pre-
operative hydration). The ‘peak serum creatinine’ was selected as the
peak value following a rise that began within the ﬁrst 48 h, peaking
within 7 days post-TAVI, as per VARC-2. The ‘discharge creatinine’ was
the ﬁnal serum creatinine recorded prior to discharge, which was al-
ways 1–2 days prior to discharge and ‘follow-up creatinine’ the reading
recorded during a follow-up visit either at our or at the patient's local
centre between 1 and 6 months following the index procedure. Post-
operative urine output was not used to deﬁne AKI due to the different
factors inﬂuencing this such as the use of diuretics and post-operative
volume status.2.2. Procedural details
All patients were recruited following referral to our centre with
symptomatic severe AS. Following initial assessment, all patients were
discussed at a multidisciplinary team meeting attended by Cardiolo-
gists, Cardiothoracic Surgeons and Cardiac Anaesthetists. TAVI was
agreed upon following formal discussion including at least two cardiac
surgeons. All patients underwent pre-operative assessment using echo-
cardiographic assessment of left and right heart function, left heart cath-
eterisation in order to assess coronary anatomy and calibre of the aortic
root, ascending aortic, iliac and femoral arteries. In patients who were
found to suffer from signiﬁcant coronary artery disease (deﬁned as a
stenosis of N70% of a major epicardial vessel), pre-TAVI percutaneous
coronary intervention (PCI) was performed at least 1 week prior to
the TAVI procedure. From 2011 all patients had comprehensive assess-
ment by CT angiography. Lung function and carotid Doppler assessment
were also performed where indicated. All procedures were performed
in the samehospital, under general anaesthetic by experienced TAVI op-
erators. Access routes included femoral (percutaneous and surgical cut-
down), axillary, subclavian, transapical and transaortic. Patients re-
ceived either Medtronic CoreValve or Edwards LifeSciences Sapien
valves. All patients provided written informed consent prior to the pro-
cedures undertaken. Routine blood testing including renal function
tests (serum urea, creatinine and electrolytes) was performed on all
patients prior to TAVI and following TAVI on a daily basis for the ﬁrst
72 h then up to 7 days following the procedure if the serum creatinine
continued to rise. Where indicated, a ﬁnal pre-discharge blood test
was also recorded in all patients.
2.3. Statistical methods
Statistical analyses were performed using IBM SPSS Statistics
Version 21 and GraphPad Prism version 6.00 (GraphPad Software, La
Jolla California USA) using standard statistical methods with groups de-
ﬁned as described above. Continuous variables for each group were
assessed for normality using histogram analysis, normality plots and
where relevant the Shapiro–Wilk test and where normally distributed
populations were found, parametric tests such as the Student's t test
was used to compare means, or in the case of non-normally distributed
groups, the Mann–Whitney U or Wilcoxon matched-pairs signed rank
test was used as deemed appropriate. For categorical data, the Chi-
square test or Fisher's exact test was used as deemed appropriate.
Predictors of AKI were identiﬁed through univariate and multivari-
ate logistic regression analysis with data presented as odds ratio (OR),
conﬁdence intervals (CI) and p-values. Promising variables for the mul-
tivariate model were selected based upon those cited in the literature
and/or where p b 0.05 following univariate analysis.
Predictors of mortality at 1-year were identiﬁed using Cox propor-
tional hazards regression was performed, again modelling promising
variables (p b 0.05 by univariate analysis) and/or those cited in the liter-
ature. For the purposes of this analysis and to ensure all patients were
included in the mortality analysis, patients already established on
haemodialysis were considered as not having developed AKI to increase
robustness of the multivariate model.
3. Results
3.1. Population characteristics
Full baseline characteristics are displayed in Table 1. One hundred
and eighteen patients underwent 120 TAVI procedures between
December 2007 and June 2012 and all were included in this analysis.
Two patients had repeat TAVI procedures several months apart. For
the purposes of this analysis, data relating to the procedure refer-
ences the ﬁrst TAVI procedure. Overall, patients were aged 81.3 ±
7.7 years (presented as mean ± standard deviation, for all
Table 1
Baseline characteristics.
Overall CKD No-CKD p-Value
N (%) N (%) N (%)
Patient numbers 118 63 (53.4) 55 (46.6)
Age (Years) 81.3 ± 7.7 81.4 ± 6.9 81.2 ± 8.5 0.912
Male 68 (57.6) 34 (54) 34 (61.8) 0.389
Diabetes 26 (22.0) 16 (25.4) 10 (18.2) 0.346
Smoking history 52 (44.1) 31 (49.2) 21 (38.2) 0.229
Peripheral vascular disease 8 (6.8) 4 (6.3) 4 (7.3) 0.842
COPD 29 (24.6) 14 (22.2) 15 (27.3) 0.812
Prior TIA/stroke 12 (10.2) 8 (12.7) 4 (7.3) 0.316
Prior MI 30 (25.4) 19 (30.2) 11 (20.0) 0.206
Prior revascularisation
PCI 21 (17.8) 9 (14.3) 12 (21.8) 0.304
CABG 44 (37.3) 26 (41.3) 18 (32.7) 0.338
Previous valve surgery 7 (5.9) 4 (6.3) 3 (5.5) 0.837
Aortic valve data
(by echocardiography)
Peak gradient 78.5 ± 23.0 75.9 ± 23.9 81.4 ± 23.9 0.219
Aortic valve area 0.75 ± 0.35 0.72 ± 0.35 0.76 ± 0.32 0.494
Logistic EuroSCORE 20.9 ± 14.9 21.2 ± 14.1 20.6 ± 15.9 0.620
NYHA Class (I–IV) 0.327
I 17 (14.4) 10 (15.9) 7 (12.7)
II 30 (25.4) 13 (20.6) 17 (30.9)
III 62 (52.5) 33 (52.4) 29 (52.7)
IV 9 (7.6) 7 (11.1) 2 (3.6)
CCS Angina Class (0–4) 0.934
CCS 0 97 (82.2) 53 (84.1) 44 (80)
CCS 1 2 (1.7) 1 (1.6) 1 (1.8)
CCS2 8 (6.8) 4 (6.3) 4 (7.3)
CCS3 11 (9.3) 5 (7.9) 6 (10.9)
CCS4 0 (0) 0 (0) 0 (0)
Coronary artery disease 0.291
3-vessel disease 8 (6.8) 3 (4.8) 5 (9.1)
2-vessel disease 8 (6.8) 5 (7.9) 3 (5.5)
1-vessel disease 12 (10.2) 9 (14.3) 3 (5.5)
Left main stem disease 3 (2.5) 1 (1.6) 2 (3.6) 0.598
LVEF 0.787
Good (EF N50%) 78 (66.1) 39 (61.9) 38 (69.1)
Fair (EF 30–49%) 32 (27.1) 18 (28.6) 14 (25.5)
Poor (EF b30%) 8 (6.8) 5 (7.9) 3 (5.5)
Pre-op dysrhythmia 0.433
Atrial ﬁbrillation 18 (15.3) 10 (15.9) 8 (14.5)
1st degree AV Block 3 (2.5) 2 (3.2) 1 (1.8)
LBBB 3 (2.5) 1 (1.6) 2 (3.6)
RBBB 1 (0.8) 0 (0) 1 (1.8)
Paced 6 (5.1) 5 (7.9) 1 (1.8)
Pulmonary hypertensiona 35 (29.7) 16 (25.4) 19 (34.5) 0.278
Data is presented as number (%) or asmean±SDunless otherwise stated. p-Value reﬂects
difference between CKD andNo-CKD groups. CABG=coronary artery bypass graft, CCS=
Canadian Cardiovascular Society angina grading, COPD = chronic obstructive pulmonary
disease, LVEF= left ventricular ejection fraction, LBBB= left bundle branch block, LMS=
left main stem, MI = myocardial infarction, NYHA= New York Heart Association, PCI =
percutaneous coronary intervention, RBBB = right bundle branch block, SD = standard
deviation, TIA = transient ischaemic attack.
a Pulmonary hypertension deﬁned as pulmonary artery systolic pressure (PASP)
N60 mm Hg.
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all baseline serum creatinine when patients already established on
RRT were excluded was 102 ± 32 μmol/L and the pre-operative
eGFR was 61 ± 20 mL/min/1.73 m2. Sixty-four patients (53%) were
deﬁned as having CKD Stage ≥3 (CKD group), whilst 55 patients
(47%) were deﬁned as having CKD Stage ≤2 (No-CKD group)
(Fig. 1A). The peak aortic valve gradient was 75.9 ± 23.9 mm Hg
and 81.4 ± 23.5 mm Hg and the mean Logistic EuroSCORE was
21.2 ± 14.1% and 20.6 ± 15.9% for CKD and No-CKD respectively.
In each group, 52% and 53% of the patients were classed as suffering
NYHA III heart failure symptoms with the vast majority of patients
suffering little in the way of pre-procedural angina for CKD and No-
CKD groups respectively. No signiﬁcant differences in the groups
(other than renal parameters) existed following statistical analysis.3.2. Procedural details
Two patients who underwent repeat procedures did so for signi-
ﬁcant paravalvar regurgitation after 1 and 4 months of the ﬁrst proce-
dure. The CKD group received a signiﬁcantly lower contrast volume
(151.6 ± 62.4 vs. 195.0 ± 56.8 mL, p= 0.0002), otherwise no signiﬁ-
cant differences existed in the procedural practices between the two
groups. Themajority had theMedtronic CoreValve implanted.More pa-
tientswhohad theEdward LifeSciences valvewas implanted featured in
the CKD group compared to No-CKD, though this was not statistically
signiﬁcant. Full procedural data is shown in Table 2.
3.3. Effect of TAVI on renal function
In total, four patients were on dialysis or haemoﬁltration prior to
TAVI; three were established on haemodialysis for more than six-
weeks prior to TAVI, and one was commenced on haemoﬁltration pre-
operatively, to optimise their renal parameters. These four patients
(all from the CKD group) were excluded from the reporting of pre-
and post-operative renal characteristics and AKI analysis. Serum creati-
nine levels were obtained for all patients pre-admission, post-TAVI and
at discharge. Follow-up serum creatinine values were obtained for 48%
of CKD and 51% of No-CKD patients.
The change in serum creatinine overall was 14.1 ± 34.5% and in
eGFR−6.0 ± 24.6% following TAVI. In the CKD group, there was a sig-
niﬁcant post-operative decline in eGFR followed by an improvement
to discharge, whilst at follow-up there was a return to pre-operative
eGFR. This was largely similar in the No-CKD group except that there
was no signiﬁcant drop in eGFR post-operatively but a signiﬁcant im-
provement in eGFR to discharge, which also returned to baseline at
follow-up (Fig. 1B). These ﬁndings were essentially mirrored by serum
creatinine changes during the post-operative and follow-up periods
for each group (Fig. 1C). Further detail of the renal parameters for
each group is presented in Table 3.
Twenty-four patients overall (21.1%) developed AKI (Stages 1–3)
and for each group was 23.7% and 14.5% for CKD and No-CKD respec-
tively (p = 0.455). New post-operative RRT was required in 8.5% in
CKD and 3.6% in No-CKD (p = 0.438), none of who required on-going
haemodialysis by the time of discharge. The contribution of each
group to AKI is shown graphically in Fig. 2A.
Using a binary logistic regression model, which included data from
all 114 patients not previously dialysed, amultivariatemodel was creat-
ed identifying predictors of AKI from those cited in the literature and
promising variables from univariate analysis (Nagelkerke R2 = 0.248).
Pre-existing diabetes mellitus (OR [95% CI] = 4.58 [1.58–13.27], p =
0.005) was found to be a signiﬁcant independent predictor of develop-
ingAKI,whilst an elevated baseline serumcreatinine also did somargin-
ally (OR [95% CI] = 1.02 [1.00–1.03], p = 0.026) following TAVI
(Table 4).
3.4. Effect of using the updated VARC-2 Consensus Document to deﬁne AKI
We opted to use the recently updated VARC-2 guidelines, meaning
that peak serum creatinine rises could be tracked for up to seven days
following TAVI, as opposed to 72 h in the one-hundred and fourteen pa-
tients not already on prior haemodialysis. In approximately one-third of
patients (32%) the creatinine peaked between the 72-hour to 7-day pe-
riod. Three (2.6%) patients, were re-deﬁned as suffering post-TAVI AKI
and three (2.6%) of the patients described as AKIN Stage 1 AKI were
reclassiﬁed as suffering AKIN Stage 3 AKI when using the VARC-2 7-
day threshold (Supplementary Table 3). All three patients redeﬁned as
suffering AKI using VARC-2 belonged to the CKD group, whilst one pa-
tient of the three who had their AKIN stage reclassiﬁed belonged to
the No-CKD group. Whilst this may in fact represent a relatively small
change in the overall results when comparing the two groups, in larger
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Fig. 1. The effect of TAVI on renal function. (A) Relative distribution of chronic kidney disease (CKD) severity throughout the two groups. (B and C) Changes in eGFR (box & whisker plot
denotingmedian, 10th, 90th centiles and outliers) and serum creatinine (SCr, line graphs) for each group as time-course changes before and after TAVI. Follow-up serum creatinine values
between 1 and 6 months following discharge were available for 48% and 51% of the CKD and No-CKD groups respectively. * denotes p b 0.05, ‘ns’ denotes p-value not signiﬁcant.
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fying AKI rates and severity.
3.5. Mortality and morbidity
Patients were followed up for a mean of 35.6 ± 21.3 months, with
on-going follow-up in either our hospital or their local cardiac centres.
All surviving patients remain on our TAVI registry and continue to at-
tend for regular follow-up. The overall 30-day mortality was ﬁve pa-
tients (4.2%) and for CKD and No-CKD patients, four (6.3%) and one
(1.8%) respectively (p = 0.370). Of the ﬁve patients who died, the pa-
tient from theNo-CKD group died immediately following an emergency
TAVI whist in cardiogenic shock. One patient had been on long-term
haemodialysis prior to TAVI and died 28 days following the procedure
from a cardiac cause of death. Two other patients who died within30 days required post-TAVI haemoﬁltration; one for post-operative
oliguria and acidosis, the other for persistent acidosis following a cardio-
respiratory arrest four days following TAVI.
The cumulative 6-month mortality rates for the CKD and No-CKD
groups were eight (12.7%) and six (10.9%; p = 0.764) and the 1-year
mortality rates, eleven (17.8%) and ten (18.2%) respectively (p =
0.919). Only one peri-procedural MI occurred overall from a No-CKD
patient and the rates of CVA were equally low at fewer than 5% in
both groups. Kaplan–Meier survival curves demonstrated no signiﬁcant
difference in overall survival following TAVI when comparing both
groups (Fig. 3). There were four (7.3%) late vascular complications re-
quiring surgical intervention in the No-CKD compared to one (1.6%) in
CKD group. The overall length of stay was 11.8 ± 12.1 days; 11.3 ±
10.6 days for CKD and 12.4 ± 13.6 days for No-CKD. Further details
are in Table 5.
Table 2
Procedural details.
Overall CKD No-CKD p-Value
N (%) N (%) N (%)0
Patient numbers 118 63 (53.4) 55 (46.6)
Urgent/Emergent procedure 2 (1.7) 1 (1.6) 1 (1.8) 1.000
Percutaneous valve type 0.060
Medtronic CoreValve 107 (90.7) 54 (85.7) 53 (96.4)
Edward LifeSciences 11 (9.3) 9 (14.3) 2 (3.6)
Delivery route 0.532
Femoral (Percutaneous) 90 (76.3) 44 (69.8) 46 (83.6)
Femoral (Surgical) 1 (0.8) 1 (1.6) 0 (0)
Axillary 1 (0.8) 1 (1.6) 0 (0)
Subclavian 4 (3.4) 2 (3.2) 2 (3.6)
Transapical 11 (9.3) 8 (12.7) 3 (5.5)
Transaortic 9 (7.6) 5 (7.9) 4 (7.3)
Contrast volume (mL) 169.7 ± 64.7 151.6 ± 62.4 195.0 ± 56.8 0.0002
Circulatory support required 2 (1.7) 1 (1.6) 1 (1.8) 1.000
Cardiogenic shock in lab 2 (1.7) 1 (1.6) 1 (1.8) 1.000
Device migration in lab 1 (0.8) 1 (1.6) 0 (0) 1.000
Emergency Valve-in-Valve in lab 2 (1.7) 2 (3.2) 0 (0) 0.498
Immediate peri-prosthetic regurgitation (by echocardiography) 0.074
None 64 (54.2) 40 (63.5) 24 (43.6)
Mild 51 (43.2) 22 (34.9) 29 (52.7)
Moderate 3 (2.5) 1 (1.6) 2 (3.6)
Severe 0 (0) 0 (0) 0 (0)
Bailout PCI in lab 1 (0.8) 1 (1.6) 0 (0) 0.534
RBC Transfusion 6 (5.3) 2 (3.4) 4 (7.3) 0.427
Data is presented as number (%) or asmean±SDunless otherwise stated. p-Value reﬂects difference between CKD andNo-CKDgroups. PCI=percutaneous coronary intervention, RBC=
red blood cell, SAVR = surgical aortic valve replacement.
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niﬁcant predictors of mortality 1-year following TAVI. All 118 patients
were included in the multivariate models. Patients who underwent
prior haemodialysis were considered as patients who ‘did not develop
AKI’, when modelling this variable. Poor baseline LV function, logistic
EuroSCORE, percentage change in eGFR and the discharge serum creat-
inine were identiﬁed through univariate analysis as potential variables
of interest. Post-operative AKI was also included in the model. In the
multivariate model, poor baseline LV function (HR [95% CI] 3.77
(1.12–12.62)) and AKI (HR [95% CI] 1.54 (0.42–5.67)) were identiﬁed
as potential predictors of 1-yearmortality, however did not reach statis-
tical signiﬁcance (Table 6).Table 3
Renal parameters of population before and after TAVI.
Overall CKD No-CKD p-Value
N (%) N (%) N (%)
Patient numbers 114 59 (51.7) 55 (48.2)
Baseline eGFR 61.8 ± 20.3 46.8 ± 8.7 77.9 ± 16.5 0.000
Post-op eGFR 58.6 ± 25.9 46.1 ± 16.3 74.5 ± 25.2 0.000
Discharge eGFR 68.2 ± 28.7 51.9 ± 16.6 85.5 ± 28.9 0.000
Follow-up eGFRa 64.0 ± 21.2 50.8 ± 13.2 77.7 ± 19.2 0.000
Baseline creatinine 101.9 ± 32.7 122.5 ± 30.2 79.9 ± 17.1 0.000
Peak 7-day Creatinine 117.2 ± 54.9 140.6 ± 56.3 91.9 ± 40.8 0.000
Δ Serum creatinine (%) 14.1 ± 34.5 13.8 ± 31.8 14.5 ± 37.6 0.908
Δ eGFR (%) −6.0 ± 24.6 −7.12 ± 25.3 −4.85 ± 24.1 0.626
AKI development 24 (21.1) 14 (23.7) 8 (14.5) 0.455
1 “Risk” 17 (14.9) 11 (18.6) 6 (10.9)
2 “Injury” 0 (0) 0 (0) 0 (0)
3 "Failure" 7 (6.1) 5 (8.5) 2 (3.6)
New RRT 7 (6.1) 5 (8.5) 2 (3.6) 0.438
Data is presented as number (%) or mean ± SD unless otherwise stated. Note, patients
undergoing pre-existing chronic haemodialysis have been excluded from analysis of
renal parameters.
p-Value reﬂects difference between CKD andNo-CKDgroups.Δ=change frombaseline to
post-TAVI, eGFR = estimated glomerular ﬁltration rate (mL/min/1.73 m2), RRT = renal
replacement therapy. Serum creatinine units are given in μmol/L.
a Follow-up eGFR data between 1 and 6 months following discharge were available for
48% and 51% of the CKD and No-CKD groups respectively.3.6. AKI versus non-AKI
Finally, in accordance with the reporting of AKI incidence in the
existing literature, we separately analysed patients according to wheth-
er they did (n= 22) or did not (n= 92) develop AKI (having excluded
those established on chronic haemodialysis). The contribution to each
group from each CKD stage is represented graphically in Fig. 2B. The fre-
quency of diabeteswas higher in the AKI group (45%vs. 16%, p=0.001).
A greater proportion of Edwards Sapien valves had been implanted in
the AKI group than the non-AKI group (25% vs. 6%; p=0.004) although
Medtronic CoreValve implantation was far more common in both
groups. The transapical route was also more frequently used in the
AKI group (22% vs. 7%, p= 0.050) although once again event number
was small. Finally, patients who developed AKI had more peri-
procedural GI bleeds (8% v. 0%, p= 0.043). We found 30-day mortality
to be signiﬁcantly higher in the AKI group (13% vs. 1%; p=0.029), con-
sistent with the literature (data is presented in full in Supplementary
Table 4).4. Discussion
TAVI is an accepted treatment for severe symptomatic AS in patients
deemed too high-risk for SAVR [38]. These older, frailer patients have
more comorbid pathologies which inﬂuence outcome following TAVI.
The development of AKI is known to affect surgical outcome and pre-
existing CKD is known predictor of post-procedure AKI. Our experience
of TAVI in a broad population of patients over a four and a half year pe-
riod has demonstrated that over half can be deﬁned as suffering with
signiﬁcant pre-existing renal impairment. We have therefore consid-
ered the safety and efﬁcacy of TAVI in presence of CKD. Although
many patients indeed have CKD, those with advanced CKD and those
on chronic RRT are excluded from large randomised clinical data that
exist to guide clinicians on appropriate therapy. We therefore set out
to assess the impact of TAVI on these patients in terms of morbidity
and mortality and in addition to assess the rate of AKI and RRT in
those with CKD.
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lished on chronic haemodialysis) was 4.2%; the 1-year mortality rate
was 17.8%. For patients with pre-existing chronic renal impairment
(CKD) these were 6.3% and 17.5% and for those without (No-CKD)
were 1.8% and 18.2% respectively.
Our ﬁndings indicate an overall rate of AKI of 21.1% and a rate of
RRT requirement of 6.1%. For CKD patients not already requiring pre-
operative dialysis, the rates of AKI and RRT were 23.7% and 8.5%, com-
pared to those with better pre-operative kidney disease status (No-
CKD), where these rates were 14.5% and 3.6% respectively. The relative
risk (RR) for developing AKI in the presence of pre-existing CKD was
1.86 (95% CI: 0.86–4.01) and for the need for RRT 2.33 (95% CI:
0.47–11.5). No patients other than those already established on chronic
haemodialysis required on-going RRT beyond discharge.Table 4
Predictors of AKI.
Variable Univariate Multivariate
OR 95% C.I. p-Value OR 95% C.I. p-Value
Age (years) 1.01 (0.95–1.07) 0.763
Male gender 0.86 (0.34–2.13) 0.751
Diabetes 4.59 (1.72–12.30) 0.002 4.58 (1.58–13.27) 0.005
Smoking history 0.89 (0.36–2.22) 0.808
Prior MI 0.72 (0.24–2.15) 0.561
PVD 1.27 (0.24–6.75) 0.777
Baseline serum
creatinine
(μmol/L)
1.02 (1.00–1.03) 0.015 1.02 (1.00–1.03) 0.026
CKD Group 2.19 (0.85–5.62) 0.104
Transapical
delivery
approach
3.68 (1.02–13.34) 0.047 3.43 (0.82–14.43) 0.092
RBC transfusion 4.14 (0.78–22.00) 0.095 4.38 (0.76–25.25) 0.098
Univariate and multivariate logistic regression analyses with data presented as odds ratio
(OR), 95% conﬁdence intervals (CI) and p-value. CKD = chronic kidney disease, MI =
myocardial infarction, PVD = peripheral vascular disease, RBC = red blood cell.
Nagelkerke R2 for multivariate model = 0.248.
Overall Comparisons
Chi-Square df p-value.
Log Rank (Mantel-Cox) 0.026 1 0.872
0 500 1000 1500 2000 2500
0.5
0.6
Survival (days)
CKD
Number at risk
63 53 37 20 8 1
No-CKD 55 45 30 14 5 1
Fig. 3. Kaplan–Meier Survival Curve comparing CKD with the No-CKD group survival.
Table below the survival curve depicts the number of subjects at risk. The comparison
showed no difference in overall survival between the CKD (red line) and No-CKD (blue
line) groups using a Log Rank (Mantel–Cox) test, p= 0.872. Censored events are marked
as vertical lines. df = degrees of freedom.
Table 5
Peri-operative morbidity and cumulative mortality data.
Overall CKD No-CKD p-Value
N (%) N (%) N (%)
Patient Number 118 63 (53.4) 55 (46.6)
Length of stay (days) 11.8 ± 12.1 11.3 ± 10.6 12.4 ± 13.6 0.364
Length of follow-up (months) 35.6 ± 21.3 36.5 ± 22.1 34.6 ± 20.3 0.591
Peri-procedural morbidity
Permanent pacing 27 (22.9) 14 (22.2) 13 (23.7) 0.355
GI bleed 2 (1.7) 0 (0) 2 (3.6) 0.219
Conversion to SAVR 3 (2.5) 2 (3.2) 1 (1.8) 1.000
Tamponade 5 (4.2) 4 (6.3) 1 (1.8) 0.370
MI 1 (0.8) 0 (0) 1 (1.8) 0.466
TIA 1 (0.8) 1 (1.6) 0 (0) 1.000
CVA 5 (4.2) 3 (4.8) 2 (3.6) 1.000
Vascular complication 5 (4.2) 1 (1.6) 4 (7.3) 0.183
Infective endocarditis
post-procedure
0 (0) 0 (0) 0 (0) –
Mortality
30 day 5 (4.2) 4 (6.3) 1 (1.8) 0.370
6 month 14 (11.9) 8 (12.7) 6 (10.9) 0.764
1 year 21 (17.8) 11 (17.5) 10 (18.2) 0.919
2 year 30 (25.4) 17 (27) 12 (21.8) 0.677
Data is presented as number (%) or asmean± SDunless otherwise stated. p-value reﬂects
difference between CKD and No-CKD groups. CVA = cerebrovascular accident, GI =
gastrointestinal, MI = myocardial infarction, SAVR = surgical aortic valve replacement,
TIA = transient ischaemic attack.
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The majority of studies investigating the impact of pre-existing CKD
on outcome following TAVI have done so as part of a whole series,
where a signiﬁcant proportion can be deﬁned as suffering from signiﬁ-
cant pre-existing renal impairment. The impact of CKD as a risk predic-
tor on outcomes in these studies has then been evaluated by comparing
groups of patients who did and did not develop AKI through multivari-
ate regression analyses.
Comparisons between surgical and transcatheter management
of severe AS in patients with CKD have been made. Bagur et al. [15]Table 6
Cox proportional hazard regression identifying predictors of 1-year mortality.
Variables Univariate
HR 95% C.I.
Age 1.00 (0.94–1.05)
Male gender 0.40 (0.15–1.09)
Diabetes 0.87 (0.32–2.39)
Smoker (ex- or current) 0.58 (0.244–1.38)
Previous MI 1.09 (0.40–2.97)
Previous stroke/TIA 0.70 (0.21–2.39)
Previous CABG 0.94 (0.39–2.27)
Pulmonary hypertensiona 1.20 (0.48–2.96)
Coronary artery disease 0.56 (0.22–1.39)
LVEF b30% 0.22 (0.08–0.67)
Logistic EuroSCORE (%) 1.03 (1.00–1.05)
CKD Group 1.01 (0.43–2.39)
Baseline serum creatinine (μmol/L) 1.00 (0.99–1.01)
Baseline eGFR (mL/min/1.73 m2) 1.01 (0.99–1.03)
Peak post-operative serum creatinine (μmol/L) 1.00 (1.00–1.01)
Post-operative eGFR nadir (mL/min/1.73 m2) 1.00 (0.98–1.02)
Δ Serum creatinine (%) 1.01 (1.00–1.01)
Δ eGFR (%) 0.98 (0.97–1.00)
Post-operative AKI 2.20 (0.88–5.45)
Discharge creatinine (μmol/L) 1.01 (1.00–1.01)
Discharge eGFR (mL/min/1.73 m2) 1.00 (0.99–1.02)
Cox proportional hazard regression performed on all 118 patients. Univariate andmultivariate data
artery bypass graft, CKD= chronic kidney disease, eGFR = estimated glomerular ﬁltration rate, L
baseline to post-TAVI.
a Pulmonary hypertension deﬁned as pulmonary artery systolic pressure (PASP) N60 mm Hcompared the CKD cohort from their analysis of patients undergoing
TAVI with a CKD group who underwent SAVR and though not
randomised, the TAVI-CKD group were older with a higher on average
logistic EuroSCORE but their rates of both AKI and need for RRT were
both lower.
Goebel et al. [39] compared ‘CKD’ and ‘non-CKD’ groups undergoing
TAVI and reported their experience of 270 patients receiving transapical
Edwards Sapien, Sapien XT or Jena Valves with approximately half de-
ﬁned as having pre-existing CKD. The AKI rate was 15.2% (20.2% in the
CKD group, 12.8% in the ‘normal’ group) and 30-day mortality was
7.8% with no difference between CKD groups. Their overall RRT rate
was 7.1%, with the ‘CKD group’ requiring RRT 10.5% and ‘non-CKD
group’ 5% of the time. These are comparable to our data, albeit in a
slightly larger cohort.
In our study, we found a trend towards a higher proportion of pa-
tients in the CKD group with diabetes, smoking history, and a previous
history of stroke, myocardial infarction (MI) and prior CABG, although
not to statistically signiﬁcance. A signiﬁcantly higher contrast volume
was used in the No-CKD cohort of patients, on average approximately
40 mL higher than CKD patients, however no other procedural differ-
ences reached statistical signiﬁcance. This was likely to be due to oper-
ators being more cautious with contrast volumes in these patients.
Neither were there any signiﬁcant differences in peri-procedural com-
plications, however the event rate was low.
During the period of time this manuscript was submitted and con-
sidered for publication, data from the FRANCE-2 Registry was published
assessing the impact of CKD on outcomes following TAVI in 2929 pa-
tients [40]. Their ﬁndings show that advanced stages of CKD (Stages 4
and 5) are associated with an increase in post-TAVI mortality in both
the short- and long-term. Furthermore, they identiﬁed the transapical
approach, advanced NYHA grade symptoms and decreasing ejection
fraction, chronic obstructive pulmonary disease and advancing age as
independent predictors of both 30-day and 1-year mortality, with CKD
Stage 3b and pulmonary hypertension additional predictors of 1-year
mortality. This represents a large, multicentre national registry with ad-
equate statistical power to investigate the differences between CKD
populations. However there are some notable differences when com-
pared to our data. Firstly, our use of VARC-2 deﬁnitions of AKI meantMultivariate
p-Value HR 95% C.I. p-Value
0.910
0.072
0.793
0.216
0.868
0.572
0.889
0.699
0.209
0.007 3.43 (0.99–11.86) 0.052
0.048 1.02 (0.99–1.05) 0.150
0.975
0.908
0.308
0.202
0.881
0.084
0.042 0.99 (0.97–1.02) 0.452
0.088 1.54 (0.42–5.67) 0.150
0.015 1.00 (1.00–1.01) 0.461
0.914
presented as hazard ratio (HR), 95% conﬁdence intervals (CI) and p-value. CABG=coronary
VEF = left ventricular ejection fraction, TIA = transient ischaemic attack, Δ= change from
g.
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days rather than 72 h. In our much smaller cohort, this resulted in 6 pa-
tients being re-classiﬁed as developing AKI or severity of disease, which
may be of importance in larger cohorts such as this one. Furthermore,
the FRANCE-2 cohort was treated predominantly with Edwards Sapien
valves (over 60%) and a consequently higher rate of transapical ap-
proach (17%).
4.2. Effect of TAVI on renal function
Transient but signiﬁcant changes in eGFR were noted post-TAVI in
the CKD group that persisted to discharge and a similar overall improve-
ment in eGFR by the time of discharge was also seen in the No-CKD co-
hort, however in both these groups eGFR returned to baseline readings
at follow-up (Fig. 1B). This may be important to consider, as a decline in
eGFR was in univariate analysis suggestive of a correlation with 1-year
mortality, despite not remaining signiﬁcant in the multivariate model
(Table 6). A number of studies have found alterations in renal function
following TAVI. Aregger et al. [22] report an improvement in GFR
7 days post-TAVI in half of their cohort, whilst Wessley et al. [41] report
almost one-third had an improvement in eGFR by discharge. Similarly,
Sinning et al. [41] report improvement in eGFR in two-thirds and
found baseline renal function was signiﬁcantly better in survivors com-
pared with non-survivors following TAVI, supporting the potential risk
CKD may confer. The explanation of improved renal function must lie
in the stepwise increase in cardiac output and renal blood ﬂow after
successful TAVI in patients with severe aortic stenosis. Schnabel et al.
[28] correlated both the lowest eGFR and a change in eGFR within the
ﬁrst 72 h following TAVI as predictors of both 30-day and 1-yearmortal-
ity in their recent study. This improvement in renal function following
TAVI was also described by D'Ascenzo et al. [42] who describe the
greatest improvement in those with poorer baseline function.
4.3. Acute kidney injury following TAVI
As one may expect, the development of VARC-2 deﬁned AKI was
higher in the CKD than No-CKD group, though not to statistical signiﬁ-
cance, with AKI rates being 23.3% and 14.5% respectively. The overall
AKI rate (21%) in our study is comparable with reported rates, which
vary fromas lowas11% [15] to as high as 41% [29] (recognisinghowever
that over 80% of the patients in this dataset had poor baseline renal
function). There are however subtle differences in the deﬁnition of
AKI (Supplementary Table 1), with most studies applying either
VARC-deﬁned or modiﬁed RIFLE criteria, whilst others use AKIN. Our
use of VARC-2 guidelines in deﬁning AKI had little impact upon the
overall results presented above (Supplementary Table 3), however in
a larger cohort this may be of greater relevance and remains an impor-
tant standardising tool in order to make results comparable between
studies.
The impact of pre-existing CKD on outcome following TAVI still
remains unclear. Our data demonstrates a trend to an increased rate of
AKI in the CKD group although this effect was attenuated somewhat
when entered into a multivariate model including other notable risk
factors from univariate analyses. Elhimidi et al. [43] demonstrated
pre-procedural serum creatinine level to be a predictor of AKI (OR
[95% CI] 3.7 (1.24–11.3); p = 0.019) as did Khawaja et al. [44] (OR
[95% CI] 1.57 (1.11–2.21); p = 0.010) who also, like our study found
pre-existing diabetes to strongly predict AKI. Other series however
have not found an association between baseline renal function or the
presence of CKD and AKI development after TAVI [29,41,45,46].
Post-operative red blood cell (RBC) transfusion has been strongly
implicated in the literature as an independent predictor of AKI following
TAVI [39,41,46–50] but did not reach statistical signiﬁcance in our
multivariate model. Only six (5.3%) patients required post-operative
RBC transfusion overall and although a greater proportion belonged to
the group who did develop AKI compared to those who did not (12.5%vs. 3.3%, p= 0.107, Supplementary Table 4) this was not a statistically
signiﬁcant difference and was therefore likely underpowered in our
model. AKI has also been shown to be independently associated with
peripheral vascular disease [41,44–46], elevated leucocyte count possi-
bly implicated as part of a systemic inﬂammatory response syndrome
(SIRS) [22,45,46,49] and a transapical approach to TAVI deployment
[22,29,48,51,52]. Contrast volume has been shown as an independent
predictor for AKI [50,53], but not consistently so [41,45,46].
Haldenwang et al. [52] compared transapical TAVI (TA-TAVI) with
minimally invasive SAVR (MI-SAVR) in terms of developing post-
operative AKI and suggested a higher risk of AKI following TA-TAVI, al-
though the TAVI cohort was signiﬁcantly older, pre-operatively had
worse baseline renal function and a higher Logistic EuroSCORE, with a
trend towards more males (found to be predictive for AKI in their mul-
tivariablemodel) and diabetics. Although the AKI ratewas not explicitly
stated for each operative technique, the overall rate of Stages 1–3 AKI
(as deﬁned by VARC-2) was over 53%, considerably higher than our
ﬁndings. In our study eleven patients (9.3%) underwent TA-TAVI with
a higher proportion of these featuring in both the CKD (Table 2) and
‘AKI’ subgroups (Supplementary Table 4) however the numbers were
too small to reach statistical signiﬁcance through univariate or multi-
variate analysis (Table 4).
4.4. Mortality
The overall 30-day mortality rate was 4.2%. This is low compared to
the published literature, where 30-day (or ‘in-hospital’) overall mortal-
ity rates have varied from 4.1% [47] — 33% [51]. Indeed, this also com-
pares favourably to the data published from the U.K. TAVI Registry
[54], which with an overlapping time frame will have included some
data from our study, where the overall 30-day mortality rate was 7.1%.
The 30-day mortality rate wasmarginally higher (6.3% vs. 1.8%; p=
0.370) in the CKD group, however the numbers were small. Cumulative
mid-term mortality was no different between patients with and with-
out CKD at 6 months, 1-year or 2-years, conﬁrmed by Kaplan–Meier
survival curve analysis (Fig. 3). Although AKI has consistently been
identiﬁed in the literature as an independent predictor of longer-term
mortality [15,29,44,45,55,56], it did not reach statistical signiﬁcance in
our analysis model. Poor baseline LV function (ejection fraction b30%)
was identiﬁed as a potential predictor of 1-year mortality through uni-
variate analysis but did not remain statistically signiﬁcantwhen entered
into themultivariatemodel. Although poor LV function has not been re-
ported in association with mid-term mortality elsewhere, worsening
New York Heart Association (NYHA) class was amongst other parame-
ters associated with increased mortality in a substudy from the
FRANCE2 Registry [56] in patients with residual aortic regurgitation
(AR) following TAVI, after a median follow-up of 306 days. Recently
published results from a substudy of the German TAVI registry [57]
analysed the outcome of patients with post-TAVI residual AR and a sig-
niﬁcantly higher proportion of patients who suffered in hospital death
had required post-operative RRT (18.3% vs. 2.1%), although neither
AKI nor RRT post-TAVI were found to be independent predictors of
mid-term mortality.
4.5. Limitations
We acknowledge that this is a small, single centre registry study and
therefore analyses may not have reached statistical signiﬁcance due to
small numbers. The sample size limits the use of extensive uni- and
multivariate analyses and therefore the interpretation of data presented
must take this into account. As a single centre study, the application of
our ﬁndings to other centres may also be subject to individual practices
that could potentially alter patient selection and outcome. Additionally,
although prospectively collected, the analysis represents a post hoc
non-pre-speciﬁed retrospective analysis performed and is therefore
open to confounding variables not collected and bias in study design.
17M.S. Rahman et al. / IJC Heart & Vasculature 8 (2015) 9–185. Conclusion
We have reported our experience of TAVI in patients with CKD
including those on chronic RRT.Wewould suggest TAVI to be an accept-
able treatment strategy for this older, frailer cohort with symptomatic
severe aortic stenosis where surgery is precluded by risk. The risk of
developing AKI however may be signiﬁcant in this cohort although we
were unable to show this to statistical signiﬁcance, but the risk of re-
quiring new RRT following TAVI and risk of death was not signiﬁcantly
impacted upon by the presence of pre-existing CKD. The presence of
pre-existing diabetes and baseline serum creatinine do however appear
to confer a greater risk of developing AKI. Post-operative AKI deve-
lopment itself was related to increased risk of short-term mortality,
underlining the importance of instituting measures to identify these
patients early and optimise their pre-operative care in order to reduce
this risk.
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